European Commission President Ursula von der Leyen said it herself The start was tough. The European Union has had a bumpy Covid19 vaccine rollout. The campaign has prompted complaints that regulators were too slow to approve the shots and led to a simmering tussle with AstraZeneca as the pharmaceutical giant repeatedly slashed its delivery commitments.
More recently, several countries briefly halted their use of the OxfordAstraZeneca vaccine amid safety concerns, a move that baffled health experts and raised questions about future uptake.The World Health Organization expressed concern earlier this week that the regions ongoing coronavirus crisis now appears more worrying than it has for several months. The warning comes as many countries introduce new measures in an attempt to curb a third wave of infections.
The health agency also described Europes vaccination campaign as unacceptably slow and said it was crucial to speed up the rollout because new infections are currently increasing in every age group apart from those aged 80 years or older. Its a messy picture, further complicated by the unique nature of European politics.
The European Commission, the executive arm of the EU, has been in charge of negotiating contracts with the pharmaceutical firms on behalf of the 27 member states. The institution is also responsible for overseeing the exports of the shots produced in the bloc. However, health policy matters are a competence of the member states, which means the…